MAIA Biotechnology CEO Details Immuno-Oncology Cancer Treatment Candidates and Development Pipeline in Letter to Shareholders
05 Mars 2024 - 2:45PM
Business Wire
- THIO-101 Phase 2 trial nears completion with survival and
response data forthcoming; exploration of multiple cancer
indications and next-generation molecules continues.
- Shareholder Letter available in Investor Relations section of
MAIA’s corporate website.
MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA” or the
“Company”), a clinical-stage biopharmaceutical company developing
targeted immunotherapies for cancer, today published a 2024 Letter
to Shareholders by Chairman and Chief Executive Officer Vlad Vitoc,
M.D., detailing the Company’s immuno-oncology cancer treatment
candidates and development pipeline.
“At MAIA Biotechnology, our tenacious pursuit of innovative
medicines to improve and extend people’s lives has led us to the
forefront of cancer research. As we wrap up the Phase 2 clinical
trial of our lead molecule THIO in non-small cell lung cancer
(NSCLC) and pursue additional indications and a pipeline of
next-generation THIO-like molecules, we are creating a robust and
transformational cancer treatment franchise,” states Dr. Vitoc at
the opening of his shareholder letter.
Letter Highlights
- THIO-101 Phase 2 clinical trial nears completion; survival and
response data updates forthcoming.
- Along with NSCLC, MAIA’s pipeline of immuno-oncology therapies
includes multiple hard-to-treat cancers.
- More than 80 THIO-like compounds have been developed for the
Company’s second-generation telomere targeting program.
- Company’s pipeline includes THIO-102 Phase 2 and THIO-103 Phase
2/3 clinical trials (planning stage), and Investigational New Drug
(IND)-enabling studies for second-generation telomere targeting
agents.
MAIA’s letter to shareholders is available at
ir.maiabiotech.com.
About MAIA Biotechnology, Inc.
MAIA is a targeted therapy, immuno-oncology company focused on
the development and commercialization of potential first-in-class
drugs with novel mechanisms of action that are intended to
meaningfully improve and extend the lives of people with cancer.
Our lead program is THIO, a potential first-in-class cancer
telomere targeting agent in clinical development for the treatment
of NSCLC patients with telomerase-positive cancer cells. For more
information, please visit www.maiabiotech.com.
Forward Looking Statements
MAIA cautions that all statements, other than statements of
historical facts contained in this press release, are
forward-looking statements. Forward-looking statements are subject
to known and unknown risks, uncertainties, and other factors that
may cause our or our industry’s actual results, levels or activity,
performance or achievements to be materially different from those
anticipated by such statements. The use of words such as “may,”
“might,” “will,” “should,” “could,” “expect,” “plan,” “anticipate,”
“believe,” “estimate,” “project,” “intend,” “future,” “potential,”
or “continue,” and other similar expressions are intended to
identify forward looking statements. However, the absence of these
words does not mean that statements are not forward-looking. For
example, all statements we make regarding (i) the initiation,
timing, cost, progress and results of our preclinical and clinical
studies and our research and development programs, (ii) our ability
to advance product candidates into, and successfully complete,
clinical studies, (iii) the timing or likelihood of regulatory
filings and approvals, (iv) our ability to develop, manufacture and
commercialize our product candidates and to improve the
manufacturing process, (v) the rate and degree of market acceptance
of our product candidates, (vi) the size and growth potential of
the markets for our product candidates and our ability to serve
those markets, and (vii) our expectations regarding our ability to
obtain and maintain intellectual property protection for our
product candidates, are forward looking. All forward-looking
statements are based on current estimates, assumptions and
expectations by our management that, although we believe to be
reasonable, are inherently uncertain. Any forward-looking statement
expressing an expectation or belief as to future events is
expressed in good faith and believed to be reasonable at the time
such forward-looking statement is made. However, these statements
are not guarantees of future events and are subject to risks and
uncertainties and other factors beyond our control that may cause
actual results to differ materially from those expressed in any
forward-looking statement. Any forward-looking statement speaks
only as of the date on which it was made. We undertake no
obligation to publicly update or revise any forward-looking
statement, whether as a result of new information, future events or
otherwise, except as required by law. In this release, unless the
context requires otherwise, “MAIA,” “Company,” “we,” “our,” and
“us” refers to MAIA Biotechnology, Inc. and its subsidiaries.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240305631171/en/
Investor Relations Contact +1 (872) 270-3518
ir@maiabiotech.com
Maia Biotechnology (AMEX:MAIA)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
Maia Biotechnology (AMEX:MAIA)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024